Funded PhD Opportunity Exploring new Epigenetic Modifying Agents to improve Immune Checkpoint therapies in Cancer

This opportunity is now closed.

Subject: Biomedical Sciences

Summary

Cancer therapy is currently undergoing a revolution due to the discovery of immune checkpoint therapy, as reflected in this year’s Nobel Prize for medicine [see ref1 for a highly readable account from the Nobel Academy]. This is based around up-regulating the body’s own immune response to the tumour. The promise of this new approach is that it can result in complete remission in a substantial fraction of cancer cases, even those previously very hard to treat.

The enormous success of immune checkpoint therapy in responsive tumours has meant that the focus has now shifted to identifying ways to “prime” non-responsive tumours so that they become amenable to the therapy. Epigenetic modifying agents (EMA) are a leading candidate for this, as recent work(refs in 2) has shown that co-treating with EMA can improve response to immune checkpoint therapy. Our lab has an internationally recognised profile in epigenetics and a long history of publication in cancer and epigenetics (eg ref3).

We have great familiarity with EMA such as the drug DAC, as well as having generated a number of model systems with epigenetic alterations, for the study of cancer as well as fundamental science. In particular, we have recently been examining the effects of DAC on human cell lines(refs in 4), as well as comparing this to the direct inhibition of the cells epigenetic machinery. Genome-wide scanning and bioinformatics analysis has led us to discover a novel pathway for up-regulation of the innate immune response in human cells using EMA, which we have tested functionally in the lab and find to be a valuable new avenue for exploration.

We now wish to recruit a motivated, hard-working student with a good background in cell biology/genetics/molecular biology and a strong desire to learn new techniques. In turn, we will provide training in a range of cutting-edge approaches, including bioinformatics, pyrosequencing, cell culture and transgenics. They will join a team working on a range of model systems including our genetically altered cell lines, CRISPR models and bespoke computer algorithms. The student will be provided with training and support, and will be expected to drive their project forward with the help and guidance of more senior lab members and our collaborators on this project, which include world-leading centres such as the SIBS institute in Shanghai (ref 5) and the CCRCB at Queens’ (ref 6). Previous graduates have found their skills in high demand in both cancer research and in other science careers.

1.Nobel Prize in Medicine 2018: Immune checkpoint therapy

2.Licht Cell 2015 162:938; Chiapinelli et all (same issue, p974)

3.Loughery JE, Dunne PD ….Walsh Hum Mol Genet ‘14 20:3241

4.O’Neill K, Irwin RE….Walsh Epigenetics & Chromatin 2018 11:12; Mackin SJ, O’Neill K and Walsh Epigenomics 2018

5.Guo F, …..Walsh CP…Xu, G-L Cell Stem Cell 2014 15:447

6.Dunne PD et al, Cancer Immunol Res 2016 4:582

Essential Criteria

  • Upper Second Class Honours (2:1) Degree or equivalent from a UK institution (or overseas award deemed to be equivalent via UK NARIC)
  • Sound understanding of subject area as evidenced by a comprehensive research proposal

Desirable Criteria

If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.

  • First Class Honours (1st) Degree
  • Masters at 65%
  • Research project completion within taught Masters degree or MRES
  • Practice-based research experience and/or dissemination
  • Experience using research methods or other approaches relevant to the subject domain
  • Work experience relevant to the proposed project
  • Publications - peer-reviewed
  • Experience of presentation of research findings
  • A comprehensive and articulate personal statement
  • Relevant professional qualification and/or a Degree in a Health or Health related area

Funding

    Vice Chancellors Research Scholarships (VCRS)

    The scholarships will cover tuition fees and a maintenance award of £15,009 per annum for three years (subject to satisfactory academic performance). Applications are invited from UK, European Union and overseas students.

    DFE

    The scholarship will cover tuition fees at the Home rate and a maintenance allowance of £15,009 per annum for three years. EU applicants will only be eligible for the fees component of the studentship (no maintenance award is provided).  For Non EU nationals the candidate must be "settled" in the UK.

Other information

The Doctoral College at Ulster University

Launch of the Doctoral College

Current PhD researchers and an alumnus shared their experiences, career development and the social impact of their work at the launch of the Doctoral College at Ulster University.

Watch Video

Reviews


My experience has been great and the people that I have worked with have been amazing

Kieran O'Donnell - 3D printing of biological cells for tissue engineering applications

Watch Video

Throughout my PhD I’ve been provided with continuous support and guidance by my supervisors and the staff at the University.I’ve also received many opportunities to further enhance my professional development in the form of teaching experience and presenting my work at conferences which will aid in my pursuit of a career in academia or industry.

William Crowe


Key Dates

Submission Deadline
Monday 18 February 2019
Interview Date
w/c 11, 18 and 25th March 2019

Campus

Coleraine campus

Coleraine campus
Our coastal and riverside campus focussing on science and health

Contact Supervisor

Professor Colum Walsh

Other Supervisors

Apply online

Visit https://www.ulster.ac.uk/applyonline and quote reference number #342812 when applying for this PhD opportunity